Skip to main content
. 2018 Apr 4;23(4):830. doi: 10.3390/molecules23040830

Figure 1.

Figure 1

Schematics of aptamers used as agonists or antagonists against cancer biomarkers. (A) Bivalent CD28 aptamer conjugate. CD28 aptamers are linked through 21 base-paired double-stranded RNA molecules; (B) Bivalent OX40 aptamer conjugate. The 3′-end stick sequence of OX40 aptamers are annealed to a DNA scaffold; (C) Bivalent OX40 aptamer conjugate. Biotin modified OX40 RNA aptamers are assembled via streptavidin; (D) Bispecific PSMA-4-4BB aptamer conjugate. A PSMA aptamer and bivalent 4-1BB aptamer are non-covalently annealed with a stick sequence; (E) An MP7 aptamer is conjugated with PEG; (F) Bivalent anti-VEGF aptamer. Two aptamers are tethered through a hexaethylene glycol spacer; (G) Anti-VEGF aptamer-antibody conjugate. This “oligobody” was developed to improve in vivo therapeutic responses.